BridgeMD
New treatment option for Pancreatic Cancer, Adult
Official title BEFAST Study, [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer
ClinicalTrials.gov ID: NCT07629609
What this study is testing
What is [68Ga]Ga-FAPI-46?
[68Ga]Ga-FAPI-46 is an investigational medicine, being studied as a potential treatment for pancreatic cancer, adult.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn if [68Ga]Ga-FAPI-46 Total Body PET/CT can diagnose patients suffering from gastroesophageal cancer and pancreatic cancer. The investigators hope that [68Ga]Ga-FAPI-46 Total Body PET/CT can improve staging and treatment evaluation for these patient groups.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- for group A
- Male or female, over 18 years old
- Patients with suspected pancreatic cancer based on morphological findings on standard imaging
- CT or MRI or [18F]FDG PET/CT evaluated on MDT with no initial sign of distant metastases
- people must have been considered suitable for curative surgery at the time of the referral
You likely can't join if
- Pregnancy or lactation
- Weight more than the maximum limit of a PET/CT-scanner bed (140 kg)
- History of allergic reaction due to compounds similar to the chemical composition of [68Ga]Ga-FAPI-46
See the full eligibility criteria
- for group A
- Male or female, over 18 years old
- Patients with suspected pancreatic cancer based on morphological findings on standard imaging
- CT or MRI or [18F]FDG PET/CT evaluated on MDT with no initial sign of distant metastases
- people must have been considered suitable for curative surgery at the time of the referral
- people must be able to read and understand the patient information in Danish to give informed consent for group B1
- Male or female over 18 years old
- Histological verified carcinoma from the lower esophagus, GEJ, or stomach
- people must be considered operable and resectable at the time of referral for MDT
- people must be able to read and understand the patient information in Danish to give informed consent for group B2
- Male or female over 18 years old
- Histological verified SRCC or PCC from the lower esophagus, GEJ, or stomach
- people with localized disease assigned to perioperative chemotherapy or people with metastatic disease assigned to palliative systemic treatment.
- people must be able to read and understand the patient information in Danish to give informed consent
- Pregnancy or lactation
- Weight more than the maximum limit of a PET/CT-scanner bed (140 kg)
- History of allergic reaction due to compounds similar to the chemical composition of [68Ga]Ga-FAPI-46
The study team makes the final eligibility decision.
Where it's taking place
- Copenhagen, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Copenhagen, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.